Stock 600976 JIANMIN PHARMACEUTICAL GROUP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Jianmin Pharmaceutical Group Co.,Ltd.

Equities

600976

CNE000001HB7

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
62.38 CNY -2.90% Intraday chart for Jianmin Pharmaceutical Group Co.,Ltd. -3.90% -4.40%
Apr. 19 Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 16 Jianmin Pharma Gets Nod to Market Asthma Drug MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Jianmin Pharma Gets Nod to Market Asthma Drug
MT
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Jianmin Pharmaceutical Group Co.,Ltd. completed the acquisition of 6.13% stake in HeraMED Limited from Hua Li Pharmaceutical Group Co.,Ltd.
CI
Jianmin Pharma Gets Nod to Market Atomoxetine Hydrochloride Oral Solution; Shares Drop 3%
MT
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Jianmin Pharma to Buy 4.5% of Australia’s Hera Med for 8.4 Million Yuan
MT
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Jianmin Pharmaceutical Group Co.,Ltd. intends to acquire Zhejiang Huafang Medical Care Co., Ltd from Holley Group Company Limited, Zhejiang Holley Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) for CNY 15.2 million.
CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Jianmin Pharmaceutical Group Co.,Ltd. intends to acquire 6.13% stake in HeraMED Limited from Hua Li Pharmaceutical Group Co.,Ltd. for AUD 2.1 million.
CI
Jianmin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Jianmin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Jianmin Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on July 7, 2020, has expired.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600976 Stock
  4. News Jianmin Pharmaceutical Group Co.,Ltd.
  5. Highlights